Two proffered paper sessions will highlight results from the ICARUS-BREAST01 phase 2 study of patritumab deruxtecan (HER3-DXd) in patients with HR positive, HER2 negative advanced breast cancer ...

Six late-breaking presentations across lung and breast cancer trials of DXd ADCs, including two Presidential Symposia at WCLC featuring datopotamab deruxtecan data First ever clinical data from ...

This mega deal, signed in October 2023 between Daiichi Sankyo and Merck & Co, was for the co-development and co-commercialization of Daiichi’s antibody‒drug conjugates (ADCs) patritumab ...

(RTTNews) - IO Biotech (IOBT) announced that the Independent Data Monitoring Committee found the data from the Pivotal Phase 3 Trial of IO102-IO103 in combination with KEYTRUDA (pembrolizumab) as ...

Shares of US protein-based vaccine developer Novavax (Nasdaq: NVAX) closed up 8.6% and added a further 1.8% to $12.60 in after-hours trading on Friday, on a positive development for its COVID-19 ...

Indian pharma major Sun Pharmaceutical Industries (BSE: 524715) says it has launched tedizolid phosphate tablets 200mg in India under the brand name Starizo. Starizo is a novel, oxazolidinone-class ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Targeted therapies and ...

(RTTNews) - Thursday, Merck & Co., Inc. (MRK) announced that Health Canada has approved its blockbuster cancer drug Keytruda for yet another indication. Keytruda in combination with antibody-drug ...

All year-end and CSV data is "as traded on the day" and ignores corporate actions (e.g. share splits) ...

A mid-stage trial of Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan has hit the mark and will form the basis of regulatory filings for the drug later this year.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This morning, the Japanese drugmaker reported updated clinical results from two clinical trials of its HER3-targeted ADC patritumab deruxtecan in metastatic breast cancer and non-small cell lung ...